Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
M Baccarani, G Saglio, J Goldman, A Hochhaus… - Blood, 2006 - ashpublications.org
The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …
Chronic myeloid leukaemia
R Hehlmann, A Hochhaus, M Baccarani - The Lancet, 2007 - thelancet.com
Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of
the genotype led to a rationally designed therapy. As a result of its well known …
the genotype led to a rationally designed therapy. As a result of its well known …
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia
R Hehlmann, M Lauseker, S Jung-Munkwitz… - Journal of clinical …, 2011 - ascopubs.org
Purpose Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400
mg/d can be unsatisfactory. Optimization of treatment is warranted. Patients and Methods In …
mg/d can be unsatisfactory. Optimization of treatment is warranted. Patients and Methods In …
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease
Background: Hydroxyurea is the only approved drug for treatment of sickle cell disease.
Objective: To synthesize the published literature on the efficacy, effectiveness, and toxicity of …
Objective: To synthesize the published literature on the efficacy, effectiveness, and toxicity of …
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintas-Cardama, J Mercer… - Leukemia, 2013 - nature.com
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
Epidemiology of chronic myeloid leukaemia (CML)
M Rohrbacher, J Hasford - Best practice & research Clinical haematology, 2009 - Elsevier
Reliable epidemiological information on chronic myeloproliferative disorders (CMPDs),
notably Philadelphia (Ph)/BCR-ABL-positive chronic myeloid leukaemia (CML), is rare …
notably Philadelphia (Ph)/BCR-ABL-positive chronic myeloid leukaemia (CML), is rare …
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
R Hehlmann, U Berger, M Pfirrmann… - Blood, The Journal …, 2007 - ashpublications.org
Early allogeneic hematopoietic stem cell transplantation (HSCT) has been proposed as
primary treatment modality for patients with chronic myeloid leukemia (CML). This concept …
primary treatment modality for patients with chronic myeloid leukemia (CML). This concept …
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
N Saban, M Bujak - Cancer chemotherapy and pharmacology, 2009 - Springer
Hydroxyurea has been used for decades and it is still valuable for the treatment of some
types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the …
types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the …
Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries
J Geissler, G Sharf, F Bombaci, M Daban… - Journal of Cancer …, 2017 - Springer
Optimal adherence to CML therapy is of key importance to maximize treatment effectiveness.
Two clinical studies (ADAGIO and Hammersmith) have proven a clear correlation between …
Two clinical studies (ADAGIO and Hammersmith) have proven a clear correlation between …